Close
Close

Amgen - Unresected Stage IIIB to IVM1c Melanoma

Partner

Not provided

Rare Disease

Unresected Stage IIIB to IVM1c Melanoma

Sponsor

Amgen

Access Program Information

The study is a phase 3b, multicenter, open-label, single-arm study designed to provide expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected stage IIIB to IVM1c melanoma. The study will also evaluate the safety and tolerability of Talimogene Laherparepvec.

Contact

Contact: (866-572-6436)

Locations
  • Switzerland

Free Newsletter